Dr. Azab joined Xenon board in 2004. He is the president and CEO of Intradigm Corporation. He brings more than 20 years of experience in pharmaceutical drug development. His past positions included leadership of medical oncology at Sanofi Pharmaceuticals (now Sanofi-Aventis) working near Paris, France, and leadership of the clinical drug development in oncology at Zeneca Pharmaceuticals (now Astra Zeneca) in the company’s R&D facility in Macclesfield, England. Dr. Azab’s immediate prior appointment was Chief Medical Officer and Executive VP of R&D at QLT Inc, in Vancouver, BC, Canada. During his career, he led drug development programs that resulted in the approval and marketing of seven different new chemical entities in the therapeutic areas of oncology, gastroenterology, urology, and ophthalmology including Casodex®, Arimidex®, Faslodex®, Photofrin®, and Visudyne®. Dr. Azab received his medical degree from Cairo University in 1979. He practiced as a medical oncologist at Institute Gustave Roussy, Villejuif, France where he received post-graduate training and degrees from the University of Paris-Sud and the University of Pierre and Marie Curie. He authored more than 40 scientific papers and book reviews.
Dr. Azab also holds an MBA degree with distinction from the Richard Ivey School of Business, University of Western Ontario in Canada. He is a member of the board for Xenon Pharma Inc. as well as a member of the board for Ckemokine Therapeutics. |
